BioLife Solutions CHRO Sells 711 Shares Under 10b5-1 Plan

Rhea-AI Filing Summary

BioLife Solutions Inc. (BLFS) – Form 4 insider transaction

Chief Human Resources Officer Sarah Aebersold reported the sale of 711 shares of common stock on 16 June 2025 at a price of $22.23 per share. The transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective 11 December 2024, indicating the sale was scheduled in advance and not triggered by undisclosed information.

Following the sale, Aebersold’s direct ownership stands at 78,721 shares. Calculations from the disclosed data show the disposal represents roughly 0.9 % of her prior position (79,432 shares), suggesting only a modest reduction in personal exposure to the company’s equity.

No derivative securities were bought or sold and no additional transactions were reported. The filing contains no information about company operations, earnings, or strategic initiatives; it purely documents a routine insider trade.

Insights

Securities Analyst

TL;DR: Minor insider sale (0.9 % stake) via 10b5-1 plan; neutral signal, limited investor impact.

The reported transaction involves a small portion of the officer’s holdings, executed under a pre-established trading plan, which typically mitigates concerns about opportunistic selling. The position reduction is immaterial relative to her remaining 78,721-share stake and does not materially affect insider ownership levels at BLFS. With no accompanying operational or financial disclosures, the market signal is neutral; investors generally treat such modest, pre-planned sales as routine personal diversification rather than bearish sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S(1)		711	D	$22.23	78,721	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-11-2024.

Remarks:

	/s/ Sarah Aebersold	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BLFS shares did Sarah Aebersold sell according to the Form 4?

She sold 711 shares of BioLife Solutions common stock.

At what price were the BLFS shares sold on 16 June 2025?

The reported sale price was $22.23 per share.

What is Sarah Aebersold’s remaining direct ownership in BLFS after the sale?

She now directly holds 78,721 shares.

Was the BLFS insider sale conducted under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1(c) plan effective 11-Dec-2024.

Does the filing include any derivative transactions or additional sales?

No. No derivative securities were acquired or disposed of, and no other transactions were reported.